An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Pulse Biosciences, Inc. (PLSE) will release its financial results for Q4 and full year 2021 after market close on March 31, 2022. A conference call hosted by management will follow at 1:30 PM PT. The company is known for its innovative CellFX® System using Nano-Pulse Stimulation™ technology to treat dermatologic conditions. This system aims to offer non-thermal solutions that can improve patient outcomes. Investors can access the earnings call via dial-in or webcast.
Positive
None.
Negative
None.
HAYWARD, Calif.--(BUSINESS WIRE)--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the fourth quarter and full year of 2021 after market close on Thursday, March 31, 2022. Company management will host a corresponding conference call beginning at 1:30pm Pacific Time.
Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of applications for which an optimal solution remains unfulfilled. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit pulsebiosciences.com to learn more.
To stay informed about the CellFX System, please visit CellFX.com and sign-up for updates.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
When will Pulse Biosciences (PLSE) report its financial results?
Pulse Biosciences will report its financial results for Q4 and full year 2021 on March 31, 2022.
What time will the Pulse Biosciences (PLSE) conference call take place?
The conference call will begin at 1:30 PM Pacific Time.
How can I listen to the Pulse Biosciences (PLSE) earnings call?
Investors can listen to the earnings call by dialing 1-877-705-6003 domestically or 1-201-493-6725 internationally, or via webcast at their investor relations website.
What technology does Pulse Biosciences (PLSE) use in its products?
Pulse Biosciences utilizes Nano-Pulse Stimulation™ technology in its CellFX® System to treat dermatologic conditions.
